Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Ali Alqahtani, MD


June 17, 2022

Testing for microsatellite instability and mismatch repair provides needed information for the use of pembrolizumab, a programmed death 1 inhibitor, as demonstrated by Le and colleagues and Zhao et al. Pembrolizumab was first granted accelerated approval from the US Food and Drug Administration in May 2017 for unresectable or metastatic microsatellite instability-high or deficient mismatch repair colon cancer following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. In 2020, it was also approved for first-line use in that patient population on the basis of results from the KEYNOTE-177 trial.

Learn more about precision medicine for metastatic CRC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.